



SPAFID CONNECT

Informazione Regolamentata n. 20076-24-2020	Data/Ora Ricezione 20 Aprile 2020 08:42:21	MTA
---	---	-----

Societa' : Giglio Group S.p.A.

Identificativo : 130956

Informazione
Regolamentata

Nome utilizzatore : GIGLION01 - Schranz

Tipologia : REGEM

Data/Ora Ricezione : 20 Aprile 2020 08:42:21

Data/Ora Inizio : 20 Aprile 2020 08:42:22

Diffusione presunta

Oggetto : OPENS ITS DIGITAL PLATFORMS TO
THE HEALTHCARE SECTOR. NEW
FRAMEWORK AGREEMENT WITH
SINOPHARM, ONE OF THE BIGGEST
PHARMACEUTICAL GROUPS IN THE
WORLD

Testo del comunicato

Vedi allegato.



**GIGLIO GROUP OPENS ITS DIGITAL PLATFORMS
TO THE HEALTHCARE SECTOR.**

**NEW FRAMEWORK AGREEMENT WITH SINOPHARM, ONE OF THE BIGGEST
PHARMACEUTICAL GROUPS IN THE WORLD, FOR THE IMPORT/EXPORT
OF MEDICAL PRODUCTS FROM AND FOR CHINA.**

***GIGLIO GROUP SHALL SUPPLY NOT ONLY FFP2 & FFP3 MEDICAL MASKS, SANITISING GELS,
GLOVES AND OTHER PPEs, BUT ALSO THE KITS FOR THE COVID-19 TESTS,
ALSO KNOWN AS SARS COV-2 ANTIBODY ASSAY KITS***

GIGLIO GROUP LAUNCHES ITS OWN B2C WEBSITE WWW.GIGLIOSALUTE.IT

Milan, 20 April 2020 - Giglio Group S.p.A. - e-commerce company listed on the MTA-STAR segment of Borsa Italiana, extends its activities also to the Healthcare sector, which now becomes one of its new stable business lines through its digital platforms, already specialised in the Fashion, Design and Food sectors. Giglio Group announces the conclusion of an open-ended framework agreement with Sinopharm, one of the biggest pharmaceutical groups in the world listed on the Hong Kong's stock-exchange market; Sinopharm was born from the joint venture between China National Pharmaceutical Group and the Chinese giant Fosun Pharmaceutical.

This strategic partnership shall allow for the import of PPEs such as FFP2 & FFP3 medical masks, sanitising gels, gloves, protectives suits and glasses, as well as for the supply of the innovative testing kits for the detection of Covid-19 antibodies, also known as Sars Cov-2 Antibody Assay kits. These kits allow for the detection, with one single drop of blood, of Covid-19 antibodies within 150 seconds, by making use of the Colloidal Gold Method, which boasts a precision of 97.5%. The Healthcare B2B and B2C platform of Giglio Group shall continue pursuing its activities regardless of the currently ongoing health emergency, offering a wide range of personal care products, which will become more and more sought-after in the near future.

The agreement signed with Sinopharm provides also for the export to China of pieces of medical equipment and items produced by Italian industries, thus contributing to their capillary distribution in the Asian market. Indeed, Sinopharm is the main Chinese firm in the Healthcare sector, active in R&D, production, logistics and pharmaceutical chains. The company is the sixth largest producer of vaccines worldwide, supplying for more than 80% of China's demand. Sinopharm is also the Chairman of Associations such as China Pharmaceutical Industry Association, China National Narcotic Drugs Association and China Association of Pharmaceutical Commerce, and acts as supervisor for diseases prevention and safeguard of the public health.

Giglio Group thus launches its own B2C website at www.gigliosalute.it, where single privates, professionals, craft workers and small business will be able to purchase the main PPEs needed for facing phases two and three of the health emergency.

Moreover, after reaching the goal of 10 million medical masks sold to some of the major entities, as well as private and public institutions in Italy, Giglio Group continues its collaboration with Confindustria's Small Industry Committee in the Country by placing a new batch worth €5 million, to which anyone can access by sending an e-mail to salute@giglio.org

Alessandro Giglio, Chairman and CEO of Giglio Group, declared: *"The elasticity and flexibility of both our logistics structure and our innovative digital platform, other than allowing for a quick extension of product offer, also allow us to tackle with vigour the current situation and to look ahead with optimism, already from the first half of the year. Our Company is specialised in designing, creating and managing e-commerce services internationally, and for this reason we have been forming partnerships with the major Luxury, Fashion, Food and Design brands of the world - and starting from today, we will also be serving the Healthcare sector. Food and Design sectors' e-commerce is growing significantly and we are already recording strong recovery signals from the Fashion sector of the Asian continent. The Healthcare sector now becomes our fourth product line within our global digital offer, with strong and quick growth prospects."*

Information on Giglio Group:

Founded by Alessandro Giglio in 2003 and listed on the STAR segment of Borsa Italiana ever since 2018, Giglio Group is the leading company for the design, creation and management of e-commerce platforms of Italy's most important Fashion, Design, Lifestyle and Food brands. The Company is based in Milan, but it is also present with offices in New York, Shanghai, Hong Kong, Rome, Lugano and Genoa. Thanks to its remarkable expertise, Giglio Group accompanies its customers in the online distribution of their products through a unique platform which, starting from the implementation of fully tailor-made and managed monobrand e-store, automatically connects them to world's major marketplaces. This is the uniqueness of a widespread digital distribution service that ensures 100% products' sale.

Giglio Group's External Relations: Elena Gallo, Piazza Diaz, 6 – Milan – elena.gallo@giglio.org

Press Office: Close to Media Via Caradosso, 8 - Milan Tel.+39 02 7000 6237

Nicola Guglielmi – nicola.guglielmi@closetomedia.it Cecilia Isella – cecilia.isella@closetomedia.it

Fine Comunicato n.20076-24

Numero di Pagine: 4